Who Profits From “More Research Is Needed”?
Every time a study finds that a herb, spice, or natural compound shows therapeutic potential, the public is presented with the same familiar conclusion:
“More research is needed.”
At face value, that sounds entirely reasonable. Science should be rigorous. Promising findings should be tested thoroughly. Extraordinary claims should require solid evidence.
The problem is not the statement itself.
The problem is what happens next.
Or more accurately, what doesn’t happen next.
Researchers identify a promising compound. Laboratory studies show biological activity. Animal studies demonstrate potential benefits. Traditional use may stretch back hundreds or even thousands of years. Scientific papers conclude that larger human trials should be conducted.
Then the trail often goes cold.
Five years later, the same compound is still described as “promising but insufficiently studied.” Ten years later, the conclusion may be unchanged. The question many people are now asking is simple:
If more research is needed, why isn’t it being funded?
The Patent Problem
Critics argue that the answer lies in the economics of modern medicine.
Pharmaceutical development revolves around patents. Patents create exclusivity. Exclusivity creates profit. Profit attracts investment.
When a company can secure exclusive rights to a treatment, investors may be willing to spend hundreds of millions of dollars funding clinical trials and regulatory approvals.
Natural compounds do not fit neatly into that model.
You cannot easily patent garlic.
You cannot monopolise cloves.
You cannot claim ownership of countless plants and compounds that have existed long before modern corporations.
Without the prospect of monopoly profits, the financial incentive to invest heavily in research can be dramatically reduced.
The Endless Loop
This creates what many see as a self-perpetuating cycle.
- A natural compound shows promise.
- Researchers call for more studies.
- Funding never arrives.
- Human trials are not conducted.
- The lack of human trials is cited as a reason not to recommend the treatment.
The cycle then repeats.
To critics, this is not merely a scientific problem. It is a structural problem.
The very system demanding more evidence often has little commercial interest in generating that evidence when the outcome may not be profitable.
The Trust Crisis
Public confidence has also been damaged by decades of pharmaceutical scandals, regulatory failures, concealed adverse effects, aggressive marketing campaigns, and multi-billion-dollar settlements.
Whether every criticism is justified is almost beside the point.
Trust is difficult to earn and easy to lose.
Many people now believe financial interests influence what gets researched, what gets promoted, and what ultimately reaches doctors and patients.
The ivermectin controversy amplified those concerns. Regardless of where people stand on the scientific debate, it became a symbol of a broader question:
Are research priorities being driven by public health needs, or by commercial interests?
Following The Evidence
None of this proves that every herb, supplement, or natural remedy works.
Some fail under rigorous testing.
Some prove ineffective.
Some may even prove harmful.
But that is precisely why proper research should occur.
Science is supposed to investigate uncertainty, not avoid it.
A genuinely evidence-based system would pursue promising leads wherever they originate—whether from a laboratory, a rainforest, a traditional medicine cabinet, or a farmer’s field.
The goal should be to discover what works.
Not simply what can be patented.
Because the question is no longer whether more research is needed.
The question many people are asking is:
If the evidence is promising, who benefits when that research never happens?
Leave a Reply